Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Constellation Pharmaceuticals Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2008
Status: Acquired
BioCentury | May 22, 2024
Deals
Biogen’s ‘pick and choose’ strategy in immunology leads to $1B HI-Bio takeout
Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others
BioCentury | May 16, 2024
Management Tracks
New CMO, CSO at Lantheus
Plus: Barbara Handelin named co-CEO of Transformative Biotech, and updates from Zephyr AI, Venatorx, Glen Clova and more
BioCentury | Feb 6, 2024
Deals
MorphoSys’ long run ends with €2.7B Novartis takeout
Shift to product-focused company positioned German biotech for deal giving former Constellation assets to Swiss pharma
BioCentury | Jun 13, 2023
Product Development
The transition from platform to product: Jean-Paul Kress on reshaping MorphoSys
CEO Jean-Paul Kress leads German biotech’s pivot away from its mAb legacy
BioCentury | Apr 14, 2023
Management Tracks
Editas names Reeve chair, adds Levy to board
Plus: Exelixis proposes new directors amid ongoing tussle with activist investor and updates from Jasper, CIRM, Visus, Curemark and more
BioCentury | Dec 17, 2022
Regulation
Dec. 16 Quick Takes: At long last, FDA approves Ferring’s Adstiladrin
Plus: Lilly, Sosei in small molecule discovery deal, and updates from WuXi Biologics, Avidity, Natera, ABio, Synaptogenix and more
BioCentury | Dec 7, 2022
Product Development
Dec. 6 Quick Takes: Gossamer falls on PAH data
Plus: HotSpot, AbbVie in IRF5 collaboration and updates from Leo, MorphoSys-Novartis, Pfizer-Clear Creek
BioCentury | Nov 9, 2022
Management Tracks
Zai’s Sandler heads to Mirati
Plus Huang becomes Zai CSO and updates from Aadi, VectorY, Fulcrum and Xenon
BioCentury | Oct 6, 2022
Management Tracks
LifeMine rounds out team with Stahl, Plamondon
Plus Theolytics adds Actelion vet Oakley as CFO, and updates from Capricorn, Cambrian,
BioCentury | Sep 22, 2022
Emerging Company Profile
Triana: Molecular glues for degradation and beyond
Launched this spring with $110M, the biotech discovers small molecule and macrocyclic molecular glues using machine learning and DEL screening
Items per page:
1 - 10 of 124